Amyloid and SARS-CoV-2; Alzheimer’s Drug Failure; Who Benefits From Brain Training?

Amyloid aggregation prediction algorithms identified two peptides from the SARS-CoV-2 proteome likely to form amyloids. (Nature Medicine)

The investigational anti-amyloid drug crenezumab did not show significant clinical benefit in a trial of cognitively healthy people with autosomal dominant Alzheimer’s disease in Colombia, Genentech said.

Who benefits from working memory training — and how? (Nature Human Behavior)

STAT takes a closer look at the first brain charts for the human lifespan.

Tremeau Pharmaceuticals opened an FDA new drug application and received a “may proceed” notice to expand development of rofecoxib — previously marketed as Vioxx — to include a phase III program for acute migraine, the company said.

A smart jumpsuit allowed researchers to track infants’ developing motor abilities. (Communications Medicine)

Traumatic injury to one part of the brain appeared to alter connections between neurons in other parts of the brain that were not directly damaged. (Nature Communications)

Eplontersen showed positive topline results in an interim analysis of a phase III study of hereditary transthyretin-mediated amyloid polyneuropathy, Ionis Pharmaceuticals announced.

Associations between anesthetic exposure during childhood and subsequent neurodevelopment deficits varied based on neurodevelopment domain. (JAMA Network Open)

Experts determined a research definition of Huntington’s disease including stages based on biological, clinical, and functional assessments. (Lancet Neurology)

Is it time to overhaul the “Cookie Theft” picture? (JAMA Neurology)